Publications
5808 Results
- Journal / Conference
- Gynecologic Oncology 112(3):444-449
- Year
- 2009
- Research Committee(s)
- Gynecologic
- Study Number(s)
- S0009
Phase II evaluation of neoadjuvant chemotherapy and interval debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group study S0009 [PMID19138791]
- Journal / Conference
- Investigational New Drugs 27(5):469-475
- Year
- 2009
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S0336
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) [PMID18941712; PMC3024913]
- Journal / Conference
- Journal of Clinical Oncology 27(21):3510-3517
- Year
- 2009
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0204
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation thalidomide-prednisone maintenance for untreated multiple myeloma: a Southwest Oncology Group Trial (S0204) [PMID19546405; PMC2717757]
- Journal / Conference
- Blood 113(4)793-796
- Year
- 2009
- Research Committee(s)
- Myeloma
- Study Number(s)
- SWOG-9003
Long term survival in Waldenstrom macroglobulinemia - 10 year follow-up of Southwest Oncology Group (SWOG) directed intergroup trial S9003 [PMID18931340; PMC2630265]
- Journal / Conference
- Journal of the National Cancer Institute 101(14):984-992
- Year
- 2009
- Research Committee(s)
- Breast, Gastrointestinal, Genitourinary, Gynecologic, Leukemia, Lung, and Lymphoma
- Study Number(s)
- SWOG-7436, SWOG-7524, SWOG-7713/14, SWOG-7823/24/25/26, SWOG-7827, SWOG-7924, SWOG-7925, SWOG-8124/25/26, SWOG-8232, SWOG-8241, SWOG-8313 (EST 5186), SWOG-8412, SWOG-8494 (INT-0036), SWOG-8501 (INT-0051), SWOG-8516 (INT-0067), SWOG-8591(NCI Intergroup #0035), SWOG-8600, SWOG-8738, SWOG-8812, SWOG-8994 (EST-C-0690) (INT-0086), SWOG-8997 (EST-3887) (ECOG-3887), SWOG-9031, SWOG-9308, SWOG-9509
Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328
- Journal / Conference
- Journal of Clinical Oncology 27(13):2157-2162
- Year
- 2009
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-8814, SWOG-8897
Treatment quality and outcomes of African American versus Caucasian breast cancer patients: retrospective analysis of Southwest Oncology Group studies S8814-S8897 [PMC2674002; PMID19307504]
- Journal / Conference
- Prostate Cancer Screening, 2nd edition, D. Ankerst, IM Thompson, C Tangen, eds., Humana Press, New York, NY, Ch. 25, pp. 349-360
- Year
- 2009
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000
The Selenium and Vitamin E Cancer Prevention Trial
- Journal / Conference
- Quality of Life Research 18:147-155
- Year
- 2009
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S9916
Chemotherapeutic impact on pain and global health-related quality of life in homone-refractory prostate cancer: dynamically modified outcomes analysis of a randomized controlled trial [PMC2859212; PMID19130298]
- Journal / Conference
- American Journal of Clinical Oncology 32:453-459
- Year
- 2009
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0312
A phase II study of gemcitabine and capecitabine in patients with advanced renal cell cancer (RCC): Southwest Oncology Group Study S0312 [PMID 19487915;PMC3394591]
- Journal / Conference
- Journal of Urology 181(2):512-516
- Year
- 2009
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-8949